: Data Sovereignty and AI Integration in the American Lab
The domestic landscape for drug development in the United States is increasingly defined by the marriage of "Big Tech" and "Bio-Pharma." The US Drug Discovery Informatics Market is characterized by a high concentration of specialized software firms that offer proprietary AI platforms for "De Novo" drug design. These systems allow American researchers to build molecules from scratch, atom by...